Clinical Scorecard: Brain Metastasis from Primary Vaginal Clear Cell Adenocarcinoma Unrelated to Diethylstilbestrol: A Case Study and Literature Review

At a Glance

Key Highlights

• PCCAV accounts for 5%-10% of primary vaginal cancers.
• Cerebral metastases from PCCAV are exceedingly rare.
• The patient presented with neurological symptoms and a vaginal mass.
• Histology confirmed metastatic clear cell vaginal adenocarcinoma.
• No established guidelines for managing metastatic PCCAV.

Guideline-Based Recommendations

Diagnosis

• Biopsy of the vaginal mass to confirm clear cell adenocarcinoma.
• CT imaging to assess for metastases.

Management

• Neurosurgical intervention for symptomatic brain lesions.
• Palliative care considerations for advanced disease.

Monitoring & Follow-up

• Regular assessment of neurological symptoms and disease progression.

Risks

• Poor prognosis associated with non-DES-related PCCAV.
• Increased likelihood of distant metastases.

Patient & Prescribing Data

Young females with PCCAV, particularly those without DES exposure.

Management decisions are made by the treating team due to the absence of standardized guidelines.

Clinical Best Practices

• Multidisciplinary team involvement for complex cases.
• Consideration of palliative care in advanced stages.

Related Resources & Content

• Chatterjee et al. 2021 Review